The Intersection Between Tumor Angiogenesis and Immune Suppression.

The Intersection Between Tumor Angiogenesis and Immune Suppression. Clin Cancer Res. 2019 Apr 03;: Authors: Rahma OE, Hodi FS Abstract Both immune checkpoint inhibitors (ICIs) and anti-angiogenesis agents have changed the landscape of cancer treatment in the modern era. While anti-angiogenesis agents have demonstrated activities in tumors with high vascularization including renal cell carcinoma (RCC) and colorectal cancer (CRC), the effect of ICIs have been seen mainly in immunologically recognized tumors, with highly immune infiltrative lymphocytes. The main challenge in ICIs drug development is moving their activities to non-inflamed tumors and overcoming resistance that is driven in part by the immune suppressive microenvironment. Angiogenesis factors drive immune suppression by directly suppressing the antigen-presenting cells as well as immune effector cells or through augmenting the effect of T-regulatory cells (T-regs), myeloid-derived suppressor cell (MDSCs) and tumor associate macrophages (TAMs). Those suppressive immune cells can also drive angiogenesis creating a vicious cycle of impaired immune activation. The combination of bevacizumab and ipilimumab was the first to show promising effect of anti-angiogenesis and immune checkpoint inhibitors. A plethora of similar combinations have entered the clinic since then confirming the promising effects of such approach. PMID: 30944124 [PubMed - as supplied by publisher]
Source: Clinical Cancer Research - Category: Cancer & Oncology Authors: Tags: Clin Cancer Res Source Type: research